Novartis gets a boost in blockbuster multiple sclerosis race with Roche
In the first step of what’s likely to be a long and uphill battle for the drugmaker, the FDA has accepted Novartis’s BLA submission for a new multiple sclerosis drug and given it priority review. The PDUFA date for the potential blockbuster drug is in June.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,000+ biopharma pros reading Endpoints daily — and it's free.